Genmab achieves milestone for filing Arzerra NDA in Japan
Genmab gained the payment from GlaxoSmithKline which was triggered by the NDA submission of Arzerra. The application seeks approval for the treatment of patients with chronic lymphocytic leukemia
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.